Vitamin D is essential for healthy calcium and phosphate homeostasis (1 ) . Vitamin D 3 is formed in the skin by the UV light-mediated photolysis of 7-dehydrocholesterol (1, 2 ) , whereas vitamin D 2 is obtained through the diet (1 ) . The metabolism of both vitamin D metabolites is identical in mammals. Vitamin D is converted in the liver by 25-hydroxylase to 25- 
hydroxyvitamin D [25(OH)D]
5 (3, 4 ) . Depending on calcium and phosphorus demands, D (10, 11 ) . Inactivating mutations of CYP24A1 (cytochrome P450, family 24, subfamily A, polypeptide 1) cause hypercalcemia, hypercalciuria, and increased 1,25(OH) 2 D concentrations (12) (13) (14) (15) (16) (17) (18) (19) (20) . In studies describing LC-MS/MS assays for 24,25(OH) 2 D quantification, the relationship between 25(OH)D and 24,25(OH) 2 D has been used as a nutritional marker for assessment of optimum vitamin D supplementation (21 ) . Mutations that cause reduced or complete loss of 24-hydroxylase function result in low or undetectable serum 24,25(OH) 2 D or increased 25(OH)D/24,25(OH) 2 D ratio. A ratio that could identify candidates for confirmatory genetic testing has not been defined.
Loss-of-function mutations in CYP24A1 have been identified as the underlying cause of hypercalcemia previously considered to be idiopathic. Several groups have identified patients with similar mutations in the 24-hydroxylase gene (12, 13, 15, 16, 18 -20 ) . Nonetheless, the population frequency of CYP24A1 mutations is currently not known, and a 25(OH)D/24,25(OH) 2 
Methods

PARTICIPANTS AND SAMPLES
The Mayo Clinic Institutional Review Board approved these studies. For determination of reference intervals, we used serum samples from 91 healthy individuals on whom 25(OH)D testing was ordered. There was sufficient clinical information available for all of the patients to confirm that none of them had any bone-or kidneyrelated conditions or were on medications that can affect bone/mineral metabolism. Each individual was screened by a detailed chart review, and none of the individuals from whom samples were obtained were taking drugs known to affect mineral metabolism, such as thiazide diuretics, corticosteroids, anticonvulsant drugs, or bisphosphonates. Patients with kidney stones were excluded. No individual had other kidney, gastrointestinal, or bone diseases known to affect vitamin D metabolism. Study participants were not taking vitamin D or calcium supplements, or if they were, were taking Յ1000 mg calcium per day and Յ1000 IU vitamin D 3 ), followed by 500 L hydrochloric acid (0.2 N) 15 min later. After mixing, we applied the sample to a BondElut (C18, 250 mg, 6 mL) cartridge (Varian Instruments), which was washed once with 2 mL of 70:30 methanol:water (1.4 mL methanol:0.6 mL water) and once with 2 mL of 90:10 hexane:methylene chloride (1.8 mL hexane:0.2 mL methylene chloride). Vitamin D metabolites were eluted with 2 mL of 90:10 hexane:isopropyl alcohol (1.8 mL hexane:0.2 mL isopropyl alcohol). Eluents were dried and derivatized with 4-phenyl-1,2,4,-
The derivatized vitamin D metabolites were separated by liquid chromatography at a flow rate of 0.25 mL/min on an Agilent XDB-C8, 2.1 ϫ 50-mm column over 7.25 min with a methanol-H 2 O-ammonium formate (1 mM) linear gradient (60%-95%). Mass spectrometry was performed in the multiple reaction monitoring mode on a AB Sciex 5500 mass spectrometer with Analyst 1.6.2 software (AB Sciex) for data acquisition and analysis. The MS/MS conditions for measuring 24,25(OH) 2 Linearity across the analytical measurement range was determined as follows. We prepared 5 pools of admixtures by mixing high-and low-concentration samples in 75:25, 50:50, and 25:75 ratios. Each pool was assayed 3 times, and the recovery was calculated as above. Recovery of 90%-110% was considered acceptable. We assessed dilutional linearity by serially diluting a high QC sample with the 0-ng/mL standard. Serial dilutions up to 1:16 were assessed. The LOD was determined by assaying a 0-ng/mL standard 20 times in 1 day. We used limit of the blank ϭ mean blank ϩ 1.645 (SD of the blank) and LOD ϭ limit of the blank ϩ 1.645 (SD of the low concentration sample) (CLSI EP17-A13).
Carryover, interference, ion suppression, and stability studies were performed. For the assessment of ion suppression, a syringe pump was connected to the column effluent, and a solution of PTAD adducts of 24,25(OH) 2 D 2 and D 3 was infused directly into the electrospray source until a constant response was obtained.
Then a stripped serum blank and a pooled serum control were extracted and prepared after complete sample workup was injected onto the column to observe the effect of matrix suppression on the response for the continuously infused 24,25(OH) 2 The characteristics of the individuals whose samples were included to determine the reference interval are shown in Table 3 Table 4 . Among the patients who were referred for 24,25(OH) 2 D assessment from our clinical practice (n ϭ 34), 2 (patients 1 and 2 in Table 4 ) were found to have CYP24A1 mutations. Patient 1 was found to have previously undescribed mutations (p.S334V, frame shift, and p.R396W, missense mutation). Patient 2 was found to have a previously described deletional mutation, p.E143Del, and a novel missense mutation, pR396W. The p.E143Del deletional mutation was previously described by Nesterova et al. (14 ) . In both patients, other common causes of hypercalcemia such as primary hyperparathyroidism were excluded before referral for 24,25(OH) 2 (Fig. 1A, inset) . Our observation was similar to that described by Kauffmann et al. (15 ) . Despite an increase in 25(OH)D/24,25(OH) 2 D at 25(OH)D concentrations Ͻ20 ng/mL, the ratio in patients affected with deleterious CYP24A1 mutations was significantly higher (P Ͻ 0.001), with almost no overlap between unaffected and affected populations (Table 4) Fig. 1B . Pathogenic CYP24A1 mutations, although rare, should be considered in the differential diagnosis of hypercalcemia. This is particularly important in cases where other etiologies of hypercalcemia (such as primary hyperparathyroidism) have been ruled out (Fig. 1B) . (14, 16, 18, 19 (Fig. 1B) .
We recently evaluated an infant with hypercalcemia associated with vitamin D toxicity. The patient had increased serum 25 (25 ) .
One of the limitations of our study is the paucity of data in patients with kidney disease. Vitamin D metabolism is impaired in patients with kidney disease, leading to reduced production of 1,25(OH) 2 (26 ) . These patients may also develop unexplained hypercalcemia, and thus an overlap between the biochemical signs of CYP24A1 deficiency vs renal insufficiency may be observed. Because our population did not include patients with kidney disease, further studies are needed to define how 25(OH)D/ 24,25(OH) 2 D compares between patients with CYP24A1 deficiency and patients with kidney disease, and whether a different diagnostic threshold is appropriate for patients with kidney disease. This will improve the diagnostic accuracy of 25(OH)D/24,25(OH) 2 D for identifying patients with CYP24A1 mutations and healthy or impaired renal function.
In summary, our results show that increased 25(OH)D/24,25(OH) 2 D supports the diagnosis of reduced CYP24A1 activity in patients with mutations of the CYP24A1 gene (12, 13 ) . 25(OH)D/24,25(OH) 2 D Ն99 in a patient with hypercalcemia of unknown etiology warrants genetic confirmation. Since the description of patients with CYP24A1 mutations independently by 2 groups (12, 13 ) , the availability of LC-MS/MS assays for 24,25(OH) 2 D quantification has enabled diagnosis of more cases. The increase in the number of reported cases in the last few years (14, 16, 19 ) suggests that CYP24A1-associated hypercalcemia is more prevalent than originally thought. Measurement of 25(OH)D/24,25(OH) 2 D should be considered a part of the clinical workup in patients with hypercalcemia of otherwise unknown etiology.
